Drug Trial Radar · NCT06197425
Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,660
Planned (sponsor's estimate)
Start
May 7, 2026
Primary completion
May 2032
Study completion May 2032
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire DijonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase III multicentric, open-label, randomized study The main objective is to assess the efficacy on time to disease recurrence (TTR) of treating minimal residual disease diagnosed by the presence of ctDNA after full treatment (surgery + chemotherapy) in stage III or high-risk stage II colon or upper rectum adenocarcinoma
Conditions
- Colon or Upper Rectum Adenocarcinoma
Interventions
"FOLFIRI" curesDrug
(Irinotecan 180 mg/m2, leucovorine 400mg/m2, 5FU bolus 400 mg/m2, 5FU continuous infusion 2400 mg/m2) every 14 days for 6 months or until disease progression on imaging
Trifluridine curesDrug
Trifluridine tipiracil 35 mg/m2 bid during 5 days/w on week 1 and 2 every 4 weeks, for 6 months or until disease progression on imaging
BIOLOGICAL ASSESSMENTBiological
blood sample ACE markers
QuestionnairesOther
Quality of life questionnaires (QLQ-C30 ; EQ-5D-5L ; GPAQ)
Thoracic-abdomino-pelvic scan or MRIOther
Thoracic-abdomino-pelvic scan or MRI
Primary outcomes
What the sponsor says the trial is designed to measure.
- The time to recurrence (TTR)Time frame: From date of randomization until the date of first documented progression or date of death from colorectal cancer
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chu Dijon Bourgogne
Dijon, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.